Triz: Dual GP-1/GIP Agonist Research

Peptide Profiles — 2026-04-14

Triz is a 39-amino-acid synthetic peptide that activates both GP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It represents a shift in metabolic peptide research toward multi-receptor agonism.

Mechanism of Action

Triz's structure is based on native GIP, with modifications that confer dual receptor activity and extended half-life (approximately 5 days): - GP-1 receptor activation — Appetite suppression, insulinotropic effects, delayed gastric emptying - GIP receptor activation — Complementary insulinotropic effects and adipose tissue signaling - Synergistic metabolic signaling — The combination appears to drive effects beyond either single pathway

Studied Benefits

Weight Reduction The SURMOUNT trials have documented: - Average weight reductions of 20-22% at the highest doses - Superior weight outcomes compared to sema in head-to-head studies - Dose-dependent response - Sustained effects over 72+ weeks

Glycemic Control In the SURPASS program for type 2 diabetes: - HbA1c reductions of 2-2.5% at highest doses - Superior HbA1c reductions compared to selective GP-1 agonists - Favorable glucose-dependent insulin response

Metabolic Markers Studies have reported broad improvements in: - Triglycerides and lipid panels - Blood pressure - Inflammatory markers - Hepatic fat content (NAFLD/MASH research)

Obstructive Sleep Apnea Emerging research suggests potential benefits in OSA, likely mediated by weight reduction and upper airway changes.

Why Dual Agonism Matters

The success of triz has reframed metabolic peptide research: 1. GIP receptor targeting, once considered unproductive, appears beneficial when paired with GP-1 activity 2. Multi-receptor strategies may provide magnitude of effect beyond single targets 3. Triz's success catalyzed triple-agonist research (e.g., reta)

Research Considerations

• Weekly subcutaneous administration is standard
• Gradual dose escalation helps mitigate GI adverse effects
• Store lyophilized at -20°C; reconstitute with bacteriostatic water
• IGF-1 and glucose should be monitored alongside weight/composition endpoints

Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.